Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Regeneron Pharmaceuticals (NQ: REGN )

748.60 +5.25 (+0.71%)
Streaming Delayed Price Updated: 2:02 PM EST, Nov 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 392,879
Open 744.87
Bid (Size) 748.00 (1)
Ask (Size) 748.99 (7)
Prev. Close 743.35
Today's Range 735.95 - 757.55
52wk Range 736.01 - 1,211.20
Shares Outstanding 91,779,465
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Regeneron Pharmaceuticals's Options: A Look at What the Big Money is Thinking
Via Benzinga
Peering Into Regeneron Pharmaceuticals's Recent Short Interest
Via Benzinga

Performance

YTD
-17.28%
-17.28%
1 Month
-22.71%
-22.71%
3 Month
-36.85%
-36.85%
6 Month
-23.91%
-23.91%
1 Year
-6.29%
-6.29%

More News

Read More
Not-So-Big Pharma
Via Talk Markets
Check Out What Whales Are Doing With REGN
Via Benzinga
FDA To Revisit Regeneron/Sanofi's Dupixent For Rare Skin Disease
Via Benzinga
Exposures Product Safety
Dupixent® (dupilumab) sBLA Accepted for FDA Review for the Treatment of Chronic Spontaneous Urticaria (CSU)
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
28 Analysts Have This To Say About Regeneron Pharmaceuticals
Via Benzinga
Assessing Regeneron Pharmaceuticals's Performance Against Competitors In Biotechnology Industry
Via Benzinga
2 Top Growth Stocks to Buy on the Dip
Via The Motley Fool
Regeneron/Sanofi's Dupixent Approval Signals Major Treatment Breakthrough For Smokers' Lung Disease
Via Benzinga
Regeneron to Highlight Pioneering Pipeline Progress Across Multiple Modalities Spanning 10 Types of Blood Cancers and Disorders at ASH
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Regeneron Announces Investor Conference Presentations
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
This Is What Whales Are Betting On Regeneron Pharmaceuticals
Via Benzinga
Regeneron Earnings Top Views For Biotech Giant
Via Investor's Business Daily
3 Recession-Resistant Stocks: Low Beta, High Margins, Low Debt
Via MarketBeat
Topics Bankruptcy Bonds Economy
Exposures Debt Markets Economy Financial
Is It Time to Buy October's Worst-Performing Nasdaq Stocks?
Via The Motley Fool
Dupixent® (dupilumab) Approved in the European Union as the First and Only Medicine for Young Children with Eosinophilic Esophagitis
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Upstream Bio Is New On NASDAQ, Can Potentially Beat AstraZeneca's Asthma Drug On Efficacy, Analysts Say
Via Benzinga
Volatility Hits Large Cap Biopharma: Active Rebalancing May Be Required
Via Talk Markets
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Regeneron Pharmaceuticals, Inc. (REGN) on Behalf of Investors
From Glancy Prongay & Murray LLP
Via Business Wire
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Regeneron Pharmaceuticals, Inc. (REGN) on Behalf of Investors
From Law Offices of Howard G. Smith
Via Business Wire
The Law Offices of Frank R. Cruz Continues Investigation of Regeneron Pharmaceuticals, Inc. (REGN) on Behalf of Investors
From The Law Offices of Frank R. Cruz
Via Business Wire
Stock Market Retreats Before Election Day; Microsoft, Apple, Amazon, Google, Meta In Focus: Weekly Review
Via Investor's Business Daily
Why Is Regeneron Pharmaceuticals Stock Trading Lower Today?
Via Benzinga
Stocks Tumble, Nasdaq 100 Selloffs As Tech Giants Disappoint, Crypto Companies Plummet: What's Driving Markets Thursday?
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.